Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Checkpoints, bispecifics and new agents at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

42 organizations at SITC 2026 present work in checkpoints, bispecifics & new agents: 16 pharma and biotech companies, 10 universities and research institutes, 8 cancer centres and hospitals, 7 suppliers and service providers and 1 government or non-profit body. Between them they bring 44 presentations to the program. Most represented: U.S. Food and Drug Administration (8 on the program), Massachusetts General Hospital (6 on the program), MD Anderson Cancer Center (5 on the program). 34 of them have their own page in this guide. As of Sep 29, 2026.

All 242 organizations at SITC 2026 →

Showing 1–7 of 42 organizations

Organization	SITC 2026 Attendance
U.S. Food and Drug Administration Silver Spring, MD
fda.gov Government & non-profit U.S. federal agency that regulates drugs, biologics and medical devices, including cancer immunotherapies.	Session Wed Nov 4 2:10pm–2:55pm Panel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics Encanto AB Regulatory Session Wed Nov 4 3:10pm–3:55pm Panel Discussion 2: Biomarker Discovery and Digital AI Encanto AB Biomarkers · AI & data Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Talk Fri Nov 6 2:45pm–3:00pm Part of Session 106b: Human Ex Vivo Models for Immunotherapy Testing: From Tumor Explants to Tumor-on-Chip From Conventional to New Approach Methodologies: Regulatory Considerations for Immuno-Oncology Safety Assessment 301A Regulatory · Models & tech
Massachusetts General Hospital Boston, MA
massgeneral.org Cancer centres & hospitals Harvard teaching hospital in Boston and home of the Mass General Cancer Center.	Session Thu Nov 5 12:00pm–1:30pm Collaborating with Industry Encanto AB Session Fri Nov 6 1:45pm–3:25pm Mechanisms of irAEs Hall A Clinical 1:50pm–2:10pmDiet and Microbiome Drivers of Immune Related Adverse EventsUniversity of Pittsburgh 2:10pm–2:30pmUnlocking the Specificity of the Autoimmune Response in iRAE’sUCSF 2:30pm–2:50pmClinical Trials for irAEs: Where Do We Go Next?Vanderbilt University Medical Center 2:55pm–3:25pm2 abstract presentations — titles not yet released Talk Sat Nov 7 4:15pm–4:25pm Part of Session 206c: Microbiome and Metabolism Gut Microbiota Metabolite Control of Antitumor CD8 T Cell Trafficking 301A Tumor biology Session Sat Nov 7 3:30pm–4:50pm IO in Low Mutation Burden Cancers Hall A Tumor biology 3:35pm–3:55pmTargeted Therapy + ImmunotherapyJohns Hopkins University 3:55pm–4:15pmFrom the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint TherapyMD Anderson Cancer Center 4:15pm–4:35pmBeyond the Canonical Proteome: Identifying Immunogenic Targets in Ovarian TumorsMayo Clinic 4:35pm–4:50pmAbstract presentation — title not yet released Session Sat Nov 7 3:30pm–4:50pm Microbiome and Metabolism 301A Tumor biology 3:30pm–3:45pmCorrecting the Gut Microbiome Dysbiosis in OncologyCentre hospitalier de l'Université de Montréal (CHUM) 3:45pm–4:00pmToward Metabotherapy for CancerStanford University 4:00pm–4:15pmIntratumoral Bacterial Elements in Brain TumorsMoffitt Cancer Center 4:15pm–4:25pmGut Microbiota Metabolite Control of Antitumor CD8 T Cell TraffickingMassachusetts General Hospital 4:25pm–4:35pmGut Microbiome Function Shapes the Efficacy of Tumor Infiltrating Lymphocyte (TIL) Therapy in MelanomaUniversity of Pittsburgh Talk Sat Nov 7 5:40pm–5:55pm Part of Session 207d: Cellular Therapies Learnings From a CAR-T Driver Into Solid Tumor Halls BC Cell therapy Talk Sun Nov 8 10:45am–11:00am Part of Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender? Biology of anti-VEGF treatment Hall A New agents · Tumor biology
MD Anderson Cancer Center Houston, TX
mdanderson.org Cancer centres & hospitals University of Texas comprehensive cancer center in Houston focused on cancer patient care, research and education.	Session Thu Nov 5 12:00pm–1:30pm Career Paths for Physician Scientists Encanto AB Workshop Thu Nov 5 7:00pm–8:00pm Early Career Scientist Speed Mentoring 7:00pm–8:00pmSpeed Mentoring - Group Mentoring 7:00pm–7:30pmSpeed Mentoring - One-on-One 7:30pm–8:00pmSpeed Mentoring - One-on-One 2 Talk Sat Nov 7 10:00am–10:20am Part of Session 202: Spatial Biology Spatial Biomarkers of Immunotherapy Response Halls BC Biomarkers · Models & tech Talk Sat Nov 7 3:55pm–4:15pm Part of Session 206b: IO in Low Mutation Burden Cancers From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy Hall A Tumor biology Session Sat Nov 7 3:30pm–4:50pm Oral Abstract Session 3 301D 3:30pm–4:45pm5 abstract presentations — titles not yet released Talk Sun Nov 8 11:30am–11:45am Part of Session 303: COOPERATIVE BINDING: The bi-specific VEGF/PD(L)-1 Inhibitor Approach to cancer immunotherapy: Savior or Pretender? Biology and Clinical Results of Anti-VEGF+PD1 Bispecfics Hall A New agents
Stanford University Stanford, CA
stanford.edu Universities & research institutes Private research university in California, home of Stanford Medicine.	Session Thu Nov 5 12:00pm–1:30pm Collaborating with Industry on Investigator-initiated Clinical Trials Encanto AB Clinical Talk Thu Nov 5 3:25pm–3:35pm Part of Session I – Grant Writing Essentials Assembling a Successful Young Investigator and Career Development Award Application for Foundations Encanto AB Workshop Thu Nov 5 2:30pm–5:05pm Grant Writing Workshop 2:30pm–4:30pmSession I – Grant Writing Essentials 4:05pm–4:30pmThe Importance of the Patient Advocate Perspective in Research and How to Effectively Connect with Advocates 4:30pm–5:00pmSession II – Breakout Sessions 5:00pm–5:05pmClosing Workshop Thu Nov 5 2:30pm–4:30pm Session I – Grant Writing Essentials Encanto AB 2:35pm–2:45pmOverview of NIH GrantsNational Cancer Institute 2:45pm–2:55pmStructuring the Necessary Framework for a Winning GrantWeill Cornell Medicine 2:55pm–3:05pmEffective Grant Proposal Writing and Avoiding Common PitfallsUniversity of Wisconsin-Madison 3:05pm–3:15pmK or F Awards? Finding Your NIH Career Development AwardsUniversity of Pennsylvania 3:15pm–3:25pmFunding Your Research Through Industry CollaborationUniversity of Pittsburgh 3:25pm–3:35pmAssembling a Successful Young Investigator and Career Development Award Application for FoundationsStanford University 3:35pm–3:50pmConsiderations for Using AINational Cancer Institute Talk Thu Nov 5 4:30pm–5:00pm Part of Session II – Breakout Sessions Breakout Table: Grants for Physician Scientists (K08 awards and others) Encanto AB Talk Fri Nov 6 1:50pm–2:10pm Part of Session 106c: Immunosenescence Aging and T-Cell Fitness 301BC Tumor biology Talk Fri Nov 6 1:50pm–2:10pm Part of Session 106a: Combination Therapies Involving Cell Therapy Cytokine Recipes for T cell immunotherapy Halls BC Cell therapy · New agents Talk Sat Nov 7 3:45pm–4:00pm Part of Session 206c: Microbiome and Metabolism Toward Metabotherapy for Cancer 301A Tumor biology
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global biopharmaceutical company that discovers, develops and sells prescription medicines, with oncology among its main therapy areas.	Booth Exhibiting at Booth 801 Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm Workshop Wed Nov 4 2:00pm–5:00pm Biotech Regulatory Roundtable 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics 2:55pm–3:10pmNetworking Break 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI 3:55pm–4:10pmNetworking Break #2 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents 4:55pm–5:00pmClosing Remarks Workshop Wed Nov 4 2:10pm–2:55pm Panel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics Encanto AB Regulatory Session Wed Nov 4 4:10pm–4:55pm Panel Discussion 3: Regulatory Framework for New IO Agents Encanto AB Regulatory · New agents Talk Thu Nov 5 10:20am–10:30am Part of Session II: Immune Cell Engagers and Bispecifics From Bench to Bispecific: The Rilvegostomig Program at a Glance Valley of the Sun Ballroom New agents Session Thu Nov 5 12:00pm–1:30pm Collaborating with Industry Encanto AB Talk Thu Nov 5 4:30pm–5:00pm Part of Session II – Breakout Sessions Breakout Table: Interfacing with Industry (Biotech Grants) Encanto AB
Icahn School of Medicine at Mount Sinai New York, NY
icahn.mssm.edu Universities & research institutes Medical school of the Mount Sinai Health System in New York City.	Session Fri Nov 6 11:30am–12:15pm Clinical Oral Abstract Session Halls BC Clinical 11:30am–12:15pm3 abstract presentations — titles not yet released Session Sat Nov 7 5:20pm–6:40pm AI-driven Protein Design to Enhance Cancer Immunotherapy 301BC AI & data · New agents 5:26pm–5:44pmProtein Design to Improve Cell TherapiesTechnical University of Denmark 5:44pm–6:02pmDesigning protein-based hardwares for human immune systemMassachusetts Institute of Technology 6:02pm–6:20pmT cell phenotype and protein structure-informed discovery of TCRs for cell therapyNational Cancer Institute 6:20pm–6:40pm2 abstract presentations — titles not yet released Talk Sat Nov 7 6:20pm–6:40pm Part of Session 207c: Hot and Cold Tumors Hot and Cold Tumor Debate Hall A Tumor biology Session Sat Nov 7 5:20pm–6:40pm Hot and Cold Tumors Hall A Tumor biology 5:20pm–5:40pmWhat Is Meant By Hot And Cold Tumors?UCLA 5:40pm–6:00pmIdentifying Determinants of Hot and Cold Tumors by AI-Assisted Perturb-MapIcahn School of Medicine at Mount Sinai 6:00pm–6:20pm2 abstract presentations — titles not yet released 6:20pm–6:40pmHot and Cold Tumor DebateUCLA, Icahn School of Medicine at Mount Sinai, Brigham and Women's Hospital Talk Sat Nov 7 5:40pm–6:00pm Part of Session 207c: Hot and Cold Tumors Identifying Determinants of Hot and Cold Tumors by AI-Assisted Perturb-Map Hall A Tumor biology · AI & data Session Sat Nov 7 5:20pm–6:40pm Oral Abstract Session 4 301D 5:20pm–6:35pm5 abstract presentations — titles not yet released
Johns Hopkins University Baltimore, MD
jhu.edu Universities & research institutes Private research university in Baltimore, Maryland.	Workshop Thu Nov 5 12:00pm–1:30pm Early Career Scientist Meet-the-Expert Lunch 12:00pm–1:30pmBioinformatics, Big Data, and AI (Table 1) 12:00pm–1:30pmBioinformatics, Big Data, and AI (Table 2) 12:00pm–1:30pmCareer Paths for Physician Scientists 12:00pm–1:30pmCareers Outside Academia and Industry – Careers in Policy, Advocacy and Non-Profit Organizations 12:00pm–1:30pmCollaborating with Industry 12:00pm–1:30pmCollaborating with Industry on Investigator-initiated Clinical Trials 12:00pm–1:30pmHow to Navigate the Graduate Student to Postdoc Transition 12:00pm–1:30pmHow to Navigate the Postdoc to PI Transition 12:00pm–1:30pmIndustry: Building Your Career in Industry (Big Pharma) 12:00pm–1:30pmIndustry: Building Your Career in Industry (Startup and Midsize Pharma) 12:00pm–1:30pmLeadership Opportunities in Immuno-oncology (Academics and Industry) 12:00pm–1:30pmNavigating Academia as Junior Faculty (as MD or PhD) 12:00pm–1:30pmNon-science Skills Needed to be a Successful Postdoc or PI 12:00pm–1:30pmSetting Up a Successful Biotech (Midsize Pharma and Small Startups) 12:00pm–1:30pmTranslational Research: Human Samples to Lab and Back to the Clinic 12:00pm–1:30pmTranslational Research: Mice to Humans 12:00pm–1:30pmTransitioning from Academia to Industry 12:00pm–1:30pmCareers in Venture Capital and Biotechnology Investing Session Fri Nov 6 3:55pm–5:30pm Cytokine Engineering and Clinical Translation 301BC New agents 4:00pm–4:15pmAnchored Cytokine Therapy for Cancer: Engineering the Next Generation of IOMass Eye and Ear 4:15pm–4:30pmAnchored and Targeted CytokinesNew York University 4:30pm–4:45pmmRNA Based Delivery of CytokinesUniversity of Pennsylvania 4:45pm–5:25pm4 abstract presentations — titles not yet released Talk Sat Nov 7 3:50pm–4:10pm Part of Session 206a: New Avenues in Myeloid Cells Neutrophils Halls BC Tumor biology Talk Sat Nov 7 3:35pm–3:55pm Part of Session 206b: IO in Low Mutation Burden Cancers Targeted Therapy + Immunotherapy Hall A Clinical